{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-24-000136","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.459191+00:00","generated_at":"2026-05-30T07:22:34.775701+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Agios reports Q3 net income of $947.9M on $1.1B milestone payments; PYRUKYND rev $9.0M","bullets":["Net income $947.9M vs loss $91.3M YoY; driven by $1.1B payments from Royalty Pharma & Servier.","PYRUKYND net revenue $9.0M (+4% QoQ); 127 patients on therapy, 211 enrollment forms.","Completed enrollment of Phase 3 RISE UP for mitapivat in SCD; topline data expected late 2025.","Initiated Phase 2b of tebapivat in LR-MDS; FDA orphan drug designation for MDS received.","Cash, equivalents and securities $1.7B at Sept 30, 2024, up from $806.4M at Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-24-000136","json":"https://secwatch.observer/filing/0001439222-24-000136.json","markdown":"https://secwatch.observer/filing/0001439222-24-000136.md","text":"https://secwatch.observer/filing/0001439222-24-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000136/0001439222-24-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000136/agio-20241031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:22:34.775701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}